{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:19:37Z","timestamp":1792063177756,"version":"4.4.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Chemical Biology"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.cbpa.2006.06.009","type":"journal-article","created":{"date-parts":[[2006,7,24]],"date-time":"2006-07-24T09:10:12Z","timestamp":1153732212000},"page":"374-379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Case studies in current drug development: \u2018glycylcyclines\u2019"],"prefix":"10.1016","volume":"10","author":[{"given":"Phaik-Eng","family":"Sum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbpa.2006.06.009_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1749-6632.1948.tb27262.x","article-title":"Aureomycin: a product of the continuing search for new antibiotics","volume":"51","author":"Duggar","year":"1948","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cbpa.2006.06.009_bib2_1","series-title":"Frontiers In Antimicrobial Resistance","first-page":"29","article-title":"Discovery and industrialization of therapeutically important tetracyclines","author":"Nelson","year":"2005"},{"key":"10.1016\/j.cbpa.2006.06.009_bib3","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","article-title":"Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance","volume":"65","author":"Chopra","year":"2001","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.cbpa.2006.06.009_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1586\/14787210.1.1.45","article-title":"Antibiotic resistance in Staphylococcus aureus: concerns, causes and cures","volume":"1","author":"Chopra","year":"2003","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.cbpa.2006.06.009_bib5_1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2672.2005.02693.x","article-title":"Clinical significance of emergence of bacterial antimicrobial resistance in the hospital environment","volume":"99","author":"Cookson","year":"2005","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.cbpa.2006.06.009_bib6","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1021\/jm00027a023","article-title":"Glycylcyclines 1. a new generation of potent antibacterial agents through modification of 9-aminotetracyclines","volume":"37","author":"Sum","year":"1994","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2006.06.009_bib7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/138161280401221007113202","article-title":"Recent developments in tetracycline antibiotics","volume":"4","author":"Sum","year":"1998","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.cbpa.2006.06.009_bib8","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0960-894X(99)00216-4","article-title":"Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936","volume":"9","author":"Sum","year":"1999","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.cbpa.2006.06.009_bib9","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1021\/bi00474a024","article-title":"Single protein omission reconstitution studies of tetracycline binding to the 30S subunit of Escherichia coli ribosomes","volume":"29","author":"Buck","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbpa.2006.06.009_bib10","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/jac\/dkh125","article-title":"Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA","volume":"53","author":"Bauer","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib11","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0092-8674(00)00216-6","article-title":"The structure basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit","volume":"103","author":"Brodersen","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.cbpa.2006.06.009_bib12","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/emboj\/20.8.1829","article-title":"Crystal structure of complexes of the small ribosomal subunit with tetracycline, edeine and IF3","volume":"20","author":"Pioletti","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.cbpa.2006.06.009_bib13","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1128\/AAC.38.7.1658","article-title":"Inhibition of protein synthesis on tetracycline-resistant TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines","volume":"38","author":"Rasmussen","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib14","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1128\/AAC.40.9.2226","article-title":"Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M) and Tet(O)-mediated ribosomal protection","volume":"40","author":"Bergeron","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2958.1990.tb02025.x","article-title":"New perspective in tetracycline resistance","volume":"4","author":"Salyers","year":"1990","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.cbpa.2006.06.009_bib16_1","series-title":"Frontiers In Antimicrobial Resistance","first-page":"3","article-title":"Tetracycline resistance: efflux, mutation, and other mechanisms","author":"Sapunaric","year":"2005"},{"key":"10.1016\/j.cbpa.2006.06.009_bib17","series-title":"Frontiers Antimicrobial Resistance","first-page":"19","article-title":"Tetracycline resistance due to ribosomal protection proteins","author":"Roberts","year":"2005"},{"key":"10.1016\/j.cbpa.2006.06.009_bib18","doi-asserted-by":"crossref","first-page":"11829","DOI":"10.1021\/bi0506066","article-title":"Tigecycline is modified by the flavin-dependent monooxygenase TetX","volume":"44","author":"Moore","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbpa.2006.06.009_bib19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1006\/jmbi.1998.2290","article-title":"Crystal structure of the Tet repressor in complex with a novel tetracycline, 9-(N,N-dimethylglycylamido)-6-demethyl-6-deoxy-tetracycline","volume":"285","author":"Orth","year":"1999","journal-title":"J Mol Biol"},{"key":"10.1016\/j.cbpa.2006.06.009_bib20","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1128\/AAC.43.6.1523","article-title":"Nomenclature for new tetracycline resistance determinants","volume":"43","author":"Levy","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1126\/science.1111415","article-title":"Chemistry: a new route to designer antibiotics","volume":"308","author":"Khosla","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.cbpa.2006.06.009_bib22_1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1126\/science.1109755","article-title":"A convergent enantioselective route to structurally diverse 6 - deoxytetracycline antibiotics","volume":"308","author":"Charest","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.cbpa.2006.06.009_bib23","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1021\/bi952683e","article-title":"Tetracycline analogs affecting binding to Tn10-encoded Tet repressor trigger the same mechanism of induction","volume":"35","author":"Lederer","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbpa.2006.06.009_bib24","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0040-4039(00)73173-X","article-title":"Synthesis of novel tetracycline derivatives with substitution at the C-8 position","volume":"35","author":"Sum","year":"1994","journal-title":"Tetrahedon Lett"},{"key":"10.1016\/j.cbpa.2006.06.009_bib25","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bmcl.2005.09.078","article-title":"Synthesis and antibacterial activity of 9-substituted minocycline derivatives","volume":"16","author":"Sum","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.cbpa.2006.06.009_bib26","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1128\/AAC.37.11.2270","article-title":"In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines","volume":"37","author":"Testa","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib27","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1128\/AAC.43.4.738","article-title":"In vitro and In vivo antimicrobial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)","volume":"43","author":"Petersen","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1128\/AAC.48.1.323-325.2004","article-title":"In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance","volume":"48","author":"Betriu","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib29","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1128\/AAC.47.8.2644-2645.2003","article-title":"In vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 eikenella corrodens clinical isolates","volume":"47","author":"Cercenado","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib30","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1128\/AAC.47.2.533-540.2003","article-title":"Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia","volume":"47","author":"Edelstein","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib31","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1128\/AAC.48.3.1034-1036.2004","article-title":"In vitro activities of tigecycline against the Bacteroides fragilis group","volume":"48","author":"Jacobus","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib32","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/AAC.48.1.366-367.2004","article-title":"In vitro activities of tigecycline (GAR-936) against multidrug-resistant staphylococcus aureus and streptococcus pneumoniae","volume":"48","author":"Kitzis","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib33","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1128\/AAC.47.2.529-532.2003","article-title":"Activity of tigecycline (GAR-936), a novel glycylcycline, against enterococci in the mouse peritonitis model","volume":"47","author":"Nannini","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib34","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1128\/AAC.48.11.4479-4481.2004","article-title":"Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem","volume":"48","author":"Pachon-Ibanez","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib35","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1086\/367622","article-title":"Tetracycline therapy: update","volume":"36","author":"Roberts","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cbpa.2006.06.009_bib36","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dki109","article-title":"Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model","volume":"55","author":"Yin","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib37","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1128\/AAC.46.8.2595-2601.2002","article-title":"In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens","volume":"46","author":"Petersen","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib38","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1128\/AAC.47.1.216-222.2003","article-title":"Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis","volume":"47","author":"Lefort","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib39","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/AAC.44.4.943-949.2000","article-title":"In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram-positive and Gram-negative bacteria","volume":"44","author":"Van Ogtrop","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.diagmicrobio.2005.05.003","article-title":"Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000\u20132004)","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cbpa.2006.06.009_bib41","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.diagmicrobio.2005.05.004","article-title":"Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cbpa.2006.06.009_bib42","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.diagmicrobio.2005.06.010","article-title":"Activity of tigecycline tested against a global collection of enterobacteriaceae, including tetracycline-resistant isolates","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cbpa.2006.06.009_bib43","doi-asserted-by":"crossref","first-page":"219S","DOI":"10.1592\/phco.20.14.219S.35046","article-title":"Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent","volume":"20","author":"Projan","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cbpa.2006.06.009_bib44","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/AAC.47.3.972-978.2003","article-title":"Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1","volume":"47","author":"Dean","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib45","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1128\/AAC.49.3.1017-1022.2005","article-title":"Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae","volume":"49","author":"Ruzin","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib46","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/AAC.49.2.791-793.2005","article-title":"AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii","volume":"49","author":"Ruzin","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2006.06.009_bib47_1","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/nrd1857","article-title":"Fresh from the pipeline: tigecycline","volume":"4","author":"Wenzel","year":"2005","journal-title":"Nat Rev Drug Discov"}],"container-title":["Current Opinion in Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593106000822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593106000822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T02:18:00Z","timestamp":1761272280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367593106000822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S1367593106000822"],"URL":"https:\/\/doi.org\/10.1016\/j.cbpa.2006.06.009","relation":{},"ISSN":["1367-5931"],"issn-type":[{"value":"1367-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Case studies in current drug development: \u2018glycylcyclines\u2019","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbpa.2006.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}